<?php
include_once('.././common.php');
include_once(G5_PATH . '/head.php');
?>

<div id="providers" class="sub01">
    <section class="sub-visual visual01  el">
        <div class="visual-txt">
            <h2><?= $title ?></h2>
        </div>
    </section>
    <!--sub-visual-->

    <section id="sec01" class="cont-a el">
        <div class="inner">
            <div class="cont-sec">
                <h2 class="cont-tit">Dose and administration</h2>
                <p><b>Dosage</b></p>
                <ul class="cont-list">
                    <li>The recommended dosage in adults is a single intravenous (IV) infusion of 40 mg/kg administered
                        over 60 minutes. The maximum dosage of regdanvimab should not exceed 8,000 mg. Regdanvimab
                        solutions must be diluted prior to administration.</li>
                    <li>Regdanvimab should be administered as soon as possible after a positive viral test for
                        SARS-CoV-2 and within 7 days of symptom onset in adults who do not require supplemental oxygen
                        and are at increased risk<sup>*</sup> of progressing to severe COVID-19</li>
                    <li>Regdanvimab is a sterile, clear to opalescent and colourless to pale yellow solution, supplied
                        in vials of 960 mg/16 mL (60 mg/mL)</li>
                </ul>
<br><br>

                <p class="extranote"><sup>*</sup>Defined as having at least one of the following risk factors for severe COVID-19: age &gt;50 years; BMI &gt;30 kg/m<sup>2</sup>; cardiovascular disease, including hypertension; chronic lung disease, including asthma; type 1 or type 2 diabetes mellitus; chronic kidney disease, including those on dialysis; chronic liver disease; and immunosuppressed, based on investigator&rsquo;s assessment in patients randomly assigned to regdanvimab in the Phase 3 clinical trial.</p>

                
            </div>
            <!--cont-sec-->
            <div class="img-sec">
                <img src="/img/item_img02.png">
            </div>
            <!--img-sec-->
        </div>
    </section>
    <!--cont-a-->
    <section id="sec02" class="cont-b  el">
        <div class="inner">
            <h2 class="cont-tit">Administration Guide</h2>
            <ul class="cont-list">
                <li>Regdanvimab solution for infusion should be prepared and administered by a qualified healthcare
                    professional</li>
                <li>Regdanvimab should be diluted and administered intravenously over 60 minutes</li>
                <li>The rate of infusion may be slowed or interrupted if the patient develops any signs of
                    infusion-related reactions or other adverse events and appropriate resuscitation equipment should be
                    available</li>
                <li>Regdanvimab may only be administered in settings in which healthcare providers have immediate access
                    to medicinal products to treat a severe infusion reaction, including anaphylaxis. Patients should be
                    clinically monitored during administration and be observed for at least 1 hour after infusion is
                    complete</li>
            </ul>
          
            <br>
            <div class="guide-wr">
                <div class="guide-list">
                    <!-- <img src="https://via.placeholder.com/120" alt="Icon/Infographic"> -->
                    <div class="guide-icon"><img src="/img/providers/icon2_01.png">
                    </div>
                    <div class="cont-txt">
                        <h3>Molecule</h3>
                        <ul class="cont-list">
                            <li><b>Regdanvimab (CT-P59):</b> Recombinant human IgG1 monoclonal antibody directed against
                                the SARS-CoV-2 RBD</li>
                        </ul>
                    </div>
                </div>
                <div class="guide-list">
                    <div class="guide-icon"><img src="/img/providers/icon2_02.png">
                    </div>
                    <div class="cont-txt">
                        <h3>Therapeutic indications</h3>
                        <ul class="cont-list">
                            <li>Treatment of adults with COVID-19 who do not require supplemental oxygen and are at
                                increased risk<sup>*</sup> of progressing to severe COVID-19</li>
                        </ul>
                        <br>
                        <p class="extranote">*Defined as having at least one of the following risk factors for severe COVID-19: age &gt;50
                            years; BMI &gt;30 kg/m2; cardiovascular disease, including hypertension; chronic lung
                            disease, including asthma; type 1 or type 2 diabetes mellitus; chronic kidney disease,
                            including those on dialysis; chronic liver disease; and immunosuppressed, based on
                            investigator&rsquo;s assessment</p>
                    </div>
                </div>

                <div class="guide-list">
                    <div class="guide-icon"><img src="/img/providers/icon2_03.png">
                    </div>
                    <div class="cont-txt">
                        <h3>Dosage</h3>
                        <ul class="cont-list">
                            <li>In adults, a single IV infusion of <b>40 mg/kg regdanvimab administered over 60
                                    minutes</b></li>
                        </ul>
                    </div>
                </div>

                <div class="guide-list">
                    <div class="guide-icon"><img src="/img/providers/icon2_05.png">
                    </div>
                    <div class="cont-txt">
                        <h3>Preparation</h3>
                        <ul class="cont-list dt-line">
                            <li>Regdanvimab should be prepared by a qualified healthcare professional using aseptic
                                technique</li>
                            <li>Refrigerated vials should be allowed to equilibrate to room temperature (not exceeding
                                30&deg;C) for approximately 20 minutes before preparation
                                <ul class="cont-list" style="padding-left: 20px; margin: 10px 0;">
                                    <li>Do not expose vials to direct heat</li>
                                    <li>Do not shake vial(s)</li>
                                </ul>
                            </li>
                            <li>Regdanvimab is a clear to opalescent, colourless to pale yellow solution for infusion.
                                Inspect regdanvimab vial(s) visually for particulate matter and discolouration prior to
                                dilution. Should either be observed, the vial(s) must be discarded, and new vial(s)
                                should be used for preparation</li>
                            <li>Calculate total volume of regdanvimab to be administered. The volume of regdanvimab is
                                calculated as follows:
                                <div class="gr-box"><img src="/img/providers/modify01.png"></div>
                            </li>
                            <li>Calculate the total number of regdanvimab vials required:
                                <div class="gr-box"><img src="/img/providers/vials-required.png"></div>
                            </li>
                            <li>Sample calculations for patients receiving the recommended dose of 40 mg/kg of
                                regdanvimab for weights ranging from 40 kg to 120 kg is as follows:

                                <div class="cont-indt">

                                    <div class="table-wr">
                                        <table class="table-style01">
                                            <thead>
                                                <tr>
                                                    <th>Body weight (kg)</th>
                                                    <th>Total dose (mg)</th>
                                                    <th>Volume (ml)</th>
                                                    <th>Vials (n)</th>
                                                </tr>
                                            </thead>
                                            <tbody>
                                                <tr>
                                                    <td>40</td>
                                                    <td>1,600</td>
                                                    <td>27</td>
                                                    <td>2</td>
                                                </tr>
                                                <tr>
                                                    <td>60</td>
                                                    <td>2,400</td>
                                                    <td>40</td>
                                                    <td>3</td>
                                                </tr>
                                                <tr>
                                                    <td>80</td>
                                                    <td>3,200</td>
                                                    <td>53</td>
                                                    <td>4</td>
                                                </tr>
                                                <tr>
                                                    <td>100</td>
                                                    <td>4,000</td>
                                                    <td>67</td>
                                                    <td>5</td>
                                                </tr>
                                                <tr>
                                                    <td>120</td>
                                                    <td>4,800</td>
                                                    <td>80</td>
                                                    <td>5</td>
                                                </tr>
                                                <tr>
                                                    <td colspan="4">Note: If patient&rsquo;s weight is more than 200 kg,
                                                        the dose calculation should use 200 kg. The maximal recommended
                                                        dose is 8,000 mg.</td>
                                                </tr>
                                            </tbody>
                                        </table>
                                    </div>
                                </div>

                            </li>
                            <li>Dilute regdanvimab in a bag containing sodium chloride 9 mg/mL (0.9%) solution for
                                infusion. The total volume of the medicinal product and sodium chloride should be 250
                                mL:
                                <ul class="cont-list" style="padding-left: 20px; margin: 10px 0;">
                                    <li>In a 250 mL bag of sodium chloride, withdraw and discard the required volume
                                        (which is identical to the calculated volume of regdanvimab) of sodium chloride
                                        9 mg/mL (0.9%) from the infusion bag</li>
                                    <li>Withdraw the calculated volume of regdanvimab from the vial(s) using a sterile
                                        syringe</li>
                                    <li>Transfer regdanvimab to the infusion bag</li>
                                </ul>
                            </li>
                            <li>Gently invert IV bag by hand approximately 10 times to mix. <b>DO NOT SHAKE</b></li>
                        </ul>
                    </div>
                </div>


                <div class="guide-list">
                    <div class="guide-icon"><img src="/img/providers/icon2_04.png">
                    </div>
                    <div class="cont-txt">
                        <h3>Storage</h3>
                        <ul class="cont-list">
                            <li>Unopened packs should be stored in a refrigerator (2&deg;C&ndash;8&deg;C). Do not
                                freeze. Keep the medicinal product in its outer carton in order to protect from light
                            </li>
                            <li>Diluted solution for infusion should be administered immediately (as soon as practicable
                                after preparation)</li>
                            <li>If immediate administration is not possible, store the diluted regdanvimab solution
                                <b>at 2&deg;C to 8&deg;C for not more than 72 hours</b> <b>or up to 4
                                    hours at </b><b>&le;30&deg;C</b> when dilution has taken place in
                                controlled and validated aseptic conditions
                            </li>
                            <li>Product is for single use in one patient only. Any residue should be discarded</li>
                        </ul>
                    </div>


                </div>

                <div class="reference">
                    <span class="ref-tit">References</span>: Celltrion Healthcare Australia Pty Ltd. REGKIRONA Approved
                    Product Information. December 6, 2021.
                </div>
            </div>
            <!--guide-wr-->
            <div class="cont-sec">
                <h3 class="sub-tit">
                Administration 
                </h3>
                <p>Regdanvimab solution for infusion should be administered by a qualified healthcare professional. </p>
                <div class="cont-indt">
                <ul class="cont-list">
                    <li>Gather the recommended materials for infusion: Infusion set with in-line filter:
                        Polyethersulfone (PES) filter with a pore size of 1.2 &mu;m or less is recommended</li>
                    <li>Attach the infusion set to the IV bag</li>
                    <li>Prime the infusion set</li>
                    <li>Administer as an IV infusion via pump over 60 minutes</li>
                    <li>The prepared solution for infusion should not be administered simultaneously with any other
                        medicinal product</li>
                </ul>
                </div>
            </div>
            <!--cont-sec-->
        </div>
    </section>
    <!--cont-b-->
    <section id="sec03" class="cont-c  el">
        <div class="inner">
            <h2 class="cont-tit">Administration Resources</h2>
            <p><i class="p-gr fas fa-external-link-alt"></i> <b>TBC whether these
                    can
                    be re-purposed for Australian HCPs, otherwise we can just edit from
                    the PI <b class="p-gr ud-line">
                        <a href="/providers/page04.php" target="_blank"><b class="p-gr ud-line">Example
                                link</b></a></p>

            <div class="gr-box"><img src="/img/providers/administration-resources.png"></div>
        </div>
    </section>
    <!--cont-c-->
</div>
<?php
include_once(G5_PATH . '/footer.php');
?>